Catalyst Pharmaceuticals, Inc.
CPRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2,415 | $2,651 | $2,946 | $2,502 |
| - Cash | $690 | $653 | $581 | $518 |
| + Debt | $2 | $3 | $3 | $3 |
| Enterprise Value | $1,728 | $2,001 | $2,368 | $1,988 |
| Revenue | $148 | $147 | $141 | $142 |
| % Growth | 1.2% | 3.6% | -0.3% | – |
| Gross Profit | $123 | $117 | $124 | $120 |
| % Margin | 82.9% | 79.6% | 87.3% | 84.7% |
| EBITDA | $80 | $79 | $73 | $72 |
| % Margin | 54.2% | 53.7% | 51.5% | 51% |
| Net Income | $53 | $52 | $57 | $56 |
| % Margin | 35.6% | 35.6% | 40.1% | 39.4% |
| EPS Diluted | 0.42 | 0.41 | 0.45 | 0.44 |
| % Growth | 2.4% | -8.9% | 2.3% | – |
| Operating Cash Flow | $32 | $71 | $60 | $71 |
| Capital Expenditures | $0 | -$0 | $0 | -$0 |
| Free Cash Flow | $32 | $71 | $60 | $71 |